Streetbeat News

Analyst Ratings

OCUL

Piper Sandler has reaffirmed its Overweight rating on Ocular Therapeutix (NASDAQ:OCUL) and increased its price target from $10.00 to $15.00. Ocular Therapeutix's shares have risen 1.22% in the last 24 hours to $9.98. The new price target suggests a potential 50.3% increase from the current price. Ocular Therapeutix is a biotech company focusing on eye disease therapies using its hydrogel platform technology.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:00 pm

BLCO

Barclays has maintained its Equal-Weight rating on Bausch & Lomb (NYSE:BLCO) and increased its price target from $17.00 to $18.00. Bausch & Lomb, a leading vision care company, was spun off from Bausch Health in 2022. It operates in vision care, surgical, and ophthalmic pharmaceuticals, holding the largest portfolio of eye care prescriptions. The stock is currently trading at $17.55, down 0.28% over the last 24 hours. An increase to $18.00 represents a 2.56% potential upside.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 5:00 pm

GENI

Cantor Fitzgerald analyst Brett Knoblauch reiterated an Overweight rating on Genius Sports (NYSE:GENI) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:53 pm

VAC

JMP Securities analyst Aaron Hecht maintains a Market Outperform rating on Marriott Vacations (NYSE:VAC) and raises the price target from $105 to $115.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:49 pm

ADCT

ADC Therapeutics' stock price increased following RBC Capital's decision to maintain an Outperform rating and raise its price target from $6 to $8.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:47 pm

BKNG

JMP Securities analyst Nicholas Jones has maintained a Market Outperform rating on Booking Holdings (NASDAQ:BKNG) and increased the price target from $3600 to $3950.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:46 pm

VZ

Significant bearish options activity has been detected in Verizon Communications (NYSE:VZ), with a notable volume of puts compared to calls. The options market is indicating a price target range of $35.0 to $47.0 for VZ. Despite mixed sentiment among large-scale traders, the bearish sentiment prevails with 62% bearishness. Verizon's current trading volume is 6,300,926, with a slight decrease in stock price by -0.12%, and it's potentially oversold according to RSI readings. Analysts have mixed opinions, with target prices ranging from $36 to $47.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:45 pm

AAL

Financial analysts have observed a bullish trend in the options market for American Airlines Gr (NASDAQ:AAL), with a significant portion of traders showing optimism. Analysis of unusual trades revealed a bullish sentiment among 66% of traders, with a focus on a price target range of $12.0 to $25.0. The largest options trades indicate a mix of neutral, bearish, and bullish sentiments, with varying strike prices and expiration dates. American Airlines, known for its extensive fleet and major U.S. hubs, has seen its stock price slightly increase by 0.07% to $15.14. An analyst from Citigroup has upgraded the stock to Buy with a price target of $20.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 4:45 pm

COGT

Citigroup analyst David Lebowitz has maintained a Buy rating on Cogent Biosciences (COGT) and increased the price target from $11 to $13.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:45 pm

SQ

Citigroup analyst Peter Christiansen has maintained a Buy rating on Block (NYSE:SQ) and increased the price target from $76 to $86, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 4:43 pm